Duloxetine Capsule, Delayed Release
Product Images NDC 71205-005

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71205-005). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure01 (Duloxetine Fig01)

A Kaplan-Meier survival curve chart depicting the proportion of patients with relapse over time in days from randomization. The chart compares two treatments: Placebo and Duloxetine, showing the proportion of patients relapsing on the y-axis and time in days on the x-axis. Duloxetine is represented by a solid line, and placebo by a dashed line.*

FDA Label Image

Figure2 (Duloxetine Fig02)

A line graph depicting the proportion of patients with relapse over time in days from randomization. Two treatments are compared: placebo, represented by a dashed line, and duloxetine, represented by a solid line. The graph shows relapse proportions increasing over approximately 250 days, with the placebo group generally having a higher relapse proportion than the duloxetine group.*

FDA Label Image

Figure04 (Duloxetine Fig04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, illustrating higher patient improvement percentages with Duloxetine treatments compared to placebo across different levels of pain improvement.*

FDA Label Image

Figure07 (Duloxetine Fig07)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved, with Duloxetine showing higher patient improvement than placebo across most pain improvement percentages.*

FDA Label Image

Figure08 (Duloxetine Fig08)

A line graph comparing the percentage of patients improved with Duloxetine 60 mg once daily versus placebo, plotted against percent improvement in pain from baseline (BOCF). The graph shows two curves with Duloxetine displaying consistently higher patient improvement percentages across pain improvement levels ranging from greater than 0% to 100%.*

FDA Label Image

Figure09 (Duloxetine Fig09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine 60/120 mg once daily. The graph shows two lines, one with markers for placebo and one for Duloxetine, illustrating patient improvement percentages across pain reduction levels ranging from greater than 0 to 100 percent.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride depicted as a two-dimensional molecular diagram showing its aromatic rings and functional groups.*

FDA Label Image

71205-005-60 (Duloxetine Delayed Release Capsules 20mg 60s)

Duloxetine 20 mg delayed-release capsules label from Proficient Rx LP. The label states the product contains 60 capsules with each capsule containing 22.4 mg duloxetine hydrochloride equivalent to 20 mg duloxetine. Marketed by Ajanta Pharma USA Inc., made in India. Label includes NDC 71205-005-60, storage instructions, and medication guide advisory.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.